Skip to main content
Log in

TNF-α further augments natural killer cells when co-administered with an interferon inducer to irradiated, leukemic, bone-marrow-transplanted mice

  • Short Communication
  • Published:
Cancer Chemotherapy and Pharmacology Aims and scope Submit manuscript

Abstract.

Purpose: We have recently demonstrated that the interferon inducer Poly I:C significantly augments both natural killer (NK) cell numbers and the life span of leukemic, irradiated mice given syngeneic bone marrow transplants (SBMT). The cytokine tumor necrosis factor-α (TNF-α) also stimulates NK cells directly through receptor–ligand mechanisms. We have combined in the present study the NK-enhancing properties of IFN (Poly I:C-induced) and TNF-α by giving Poly I:C to leukemic mice for 8 days after irradiation and SBMT, concomitant with TNF-α during the first 4 days immediately after SBMT. All mice were sampled at day 9 following irradiation, transplant, and treatment. Methods: NK cells were identified and quantified by immunoperosidase labeling methods combined with a hematologic staining technique. Results: The data reveal that TNF-α, added to the Poly I:C administration protocol, significantly boosted NK cell numbers 2.4-fold over that achieved by Poly I:C alone. Conclusions: Since the role of NK cells in the immediate post-transplant period is (a) to destroy residual tumor cells, and (b) to produce hemopoiesis-driving cytokines, it appears that two NK cell stimulants are better than one, at least in the crucial, early post-transplant period.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Author information

Authors and Affiliations

Authors

Additional information

Electronic Publication

Rights and permissions

Reprints and permissions

About this article

Cite this article

Currier, N.L., Miller, S.C. TNF-α further augments natural killer cells when co-administered with an interferon inducer to irradiated, leukemic, bone-marrow-transplanted mice. Cancer Chemother Pharmacol 47, 185–186 (2001). https://doi.org/10.1007/s002800000222

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s002800000222

Navigation